

October 10, 2017



CEO Richard T. Schumacher Discusses Pressure BioScience's New Sales Team and Novel Products that are Fueling its Progressive Upturn

Phoenix, AZ., Oct. 10, 2017 (GLOBE NEWSWIRE) -- **Richard T. Schumacher, CEO of Pressure BioSciences, Inc. (OTCQB: PBIO) (the "Company")**, was recently interviewed on the Uptick Network Stock Day Podcast with host Everett Jolly. Starting off the interview, Mr. Schumacher discussed the benefits of adding additional personnel to Pressure BioScience's sales team, which included product revenue increases expected from these new field sales directors. Continuing the interview, Mr. Schumacher touched on the Company's stock and the steps it is taking to help bring a return on investment to its investors. Furthermore, Mr. Schumacher elaborated on the importance of Pressure BioScience's patented pressure cycling technology (PCT) platform, and discussed the Company's first two issued patents in its exciting High Pressure-Based Ultra Shear Technology (UST) platform.

In closing, Mr. Schumacher states, "This is a company comprised of very hard working, smart people - the best group with whom I have ever worked. The company has changed immensely since my last interview with Uptick, back in May. We now we have 6 sales people who we believe will significantly ramp up sales. We have a brand new instrument that has already won several awards. Because it can go much further than the previous instrument, we believe it can open many new doors for PBI in the very large biopharmaceutical space. This is a company that is not only doing well, but one that we believe has the potential to do even better. Perhaps we are that undiscovered gem for whom investors are looking."

To listen to the full interview please [click here](https://upticknewswire.com/featured-interview-ceo-ric-schumacher-of-pressure-biosciences-inc-otcqb-pbio-sept-update) or the following link:

<https://upticknewswire.com/featured-interview-ceo-ric-schumacher-of-pressure-biosciences-inc-otcqb-pbio-sept-update>

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated \$6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or "PCT") hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug development and design, bio-therapeutics characterization, soil & plant biology, forensics, and counter-bioterror applications. Major new focal market opportunities are emerging in the use of our patented,

scalable, high-efficiency Ultra Shear Technology ("UST") to create stable nanoemulsions of otherwise immiscible fluids (such as oils and water), and to prepare homogenized, extended shelf-life or room temperature stable, low-acid liquid foods that cannot be effectively prepared using existing, FDA-approved, high-pressure processing ("HPP") technologies.

Forward-Looking Statements

Statements contained in this press release regarding PBI's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2016, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link:

<http://www.pressurebiosciences.com>

Please visit PBIO on Facebook, LinkedIn, and Twitter

Source: [Uptick Newswire](#)

Investor Contacts:

Richard T. Schumacher, President & CEO

Nathan P. Lawrence, Ph.D., VP of Marketing and Sales

Pressure BioSciences, Inc.

(508) 230-1828 (T)

Source: Pressure BioSciences, Inc.